Value of thyroglobulin to 131I uptake ratio in selection of initial therapy dose of 131I in patients with differentiated thyroid carcinoma

被引:0
|
作者
Zerva, C. [1 ]
Koutsikos, J. [1 ]
Palestidis, C. [1 ]
Kounadi, E. [1 ]
Gerali, S. [1 ]
机构
[1] Alexandra Univ Hosp, Dept Nucl Med, GR-11528 Athens, Greece
来源
QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2006年 / 50卷 / 04期
关键词
differentiated thyroid carcinoma; thyroglobulin; I-131; uptake; I-131 ablative dose; therapy;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Aim To test the hypothesis that the ratio of thyroglobulin (Tg) to I-131 uptake in the thyroid bed during the immediate post-thyroidectomy work-up could be used before first I-131 treatment to detect patients with residual or metastatic thyroid cancer and justify the administration of a higher ablation dose in selected cases and a possibly better therapeutic effect. Methods. We retrospectively studied 293 patients with differentiated thyroid carcinoma that received their first I-131 treatment in our department. Patients with Tg > 100 ng/ml I-131 uptake > 10% and measurable Tg-specific autoantihodies, were excluded. According to the post-therapy total body scan (TBS), we divided them in 2 groups: group I, without metastases (negative TBS), and group II, with metastases (positive TBS). The ratio of Tg to I-131 uptake measured before the first I-131 treatment was calculated in both groups. Results. A total of 248 patients were included in the study;, 225 in group I and 23 in group II. Tg to I-131 uptake ratio was significantly lower in group I (mean 2.17 ng/ml/%, range 0-36), than in group II (mean 32.7 ng/mL/%, range 2.14-220), (P < 0.01). The sensitivity, specificity and accuracy (using a threshold ratio 7 ng/mL/% as normal) were all 95.6% for predicting a positive post-therapy TBS. Conclusion The use of a threshold ratio 7 ng/mL% as the upper limit of normal provides usefid information with higher sensitivity and specificity in identifying patients with metastatic disease creating the possibility for the selective use of higher initial iodine therapy doses.
引用
收藏
页码:348 / 354
页数:7
相关论文
共 50 条
  • [41] To Use or Not to Use 131I in Thyroid Cancer
    Metter, Darlene
    Phillips, William T.
    Walker, Ronald C.
    Blumhardt, Ralph
    CLINICAL NUCLEAR MEDICINE, 2018, 43 (09) : 670 - 671
  • [42] Therapeutic administration of 131I for differentiated thyroid cancer:: Radiation dose to ovaries and outcome of pregnancies
    Garsi, Jerome-Philippe
    Schlumberger, Martin
    Rubino, Carole
    Ricard, Marcel
    Labbe, Martine
    Ceccarelli, Claudia
    Schvartz, Claire
    Henri-Amar, Michel
    Bardet, Stephane
    de Vathaire, Florent
    JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (05) : 845 - 852
  • [43] Gonadal effect of radiation from 131I in male patients with thyroid carcinoma
    Krassas, GE
    Pontikides, N
    ARCHIVES OF ANDROLOGY, 2005, 51 (03): : 171 - 175
  • [44] Sustained and Diffuse 131I Avid Bone Metastases With Low Thyroglobulin Levels in a Patient With Papillary Thyroid Carcinoma
    Zhao, Chun-Lei
    Qiu, Zhong-Ling
    Chen, Li-Bo
    Yuan, Zhi-Bin
    Luo, Quan-Yong
    CLINICAL NUCLEAR MEDICINE, 2013, 38 (05) : 375 - 377
  • [45] The study of influence factors on 131I treatment of differentiated thyroid carcinoma with lymph node metastases
    Ye, Zhi-Yi
    Wang, Hui
    Fu, Hong-Liang
    Li, Jia-Ning
    Zou, Ren-Jian
    Gu, Zhen-Hui
    Wu, Jing-Chuan
    CLINICAL IMAGING, 2009, 33 (03) : 221 - 225
  • [46] Double-phase 131I whole body scan and 131I SPECT-CT images in patients with differentiated thyroid cancer: their effectiveness for accurate identification
    Wakabayashi, Hiroshi
    Nakajima, Kenichi
    Fukuoka, Makoto
    Inaki, Anri
    Nakamura, Ayane
    Kayano, Daiki
    Kinuya, Seigo
    ANNALS OF NUCLEAR MEDICINE, 2011, 25 (09) : 609 - 615
  • [47] To Ablate or Not to Ablate: Issues and Evidence Involved in 131I Ablation of Residual Thyroid Tissue in Patients with Differentiated Thyroid Carcinoma
    Goldsmith, Stanley J.
    SEMINARS IN NUCLEAR MEDICINE, 2011, 41 (02) : 96 - 104
  • [48] Predictors of success of the ablative/therapeutic radioiodine (131I) in differentiated thyroid cancer
    Fard-Esfahani, Armaghan
    Valipouri, Mohammad Reza
    Harsini, Sara
    Beiki, Davood
    Emami-Ardekani, Alireza
    Fallahi, Babak
    Eftekhari, Mohammad
    IRANIAN JOURNAL OF NUCLEAR MEDICINE, 2020, 28 (01): : 14 - 20
  • [49] FDG PET Predicts the Effects of 131I and Prognosis for Patients with Bone Metastases from Differentiated Thyroid Carcinoma
    Wang, Danyang
    Bai, Yongli
    Huo, Yanlei
    Ma, Chao
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 13223 - 13232
  • [50] Value of Postoperative Thyroglobulin and Ultrasonography for the Indication of Ablation and 131I Activity in Patients with Thyroid Cancer and Low Risk of Recurrence
    Rosario, Pedro Weslley
    Malard Xavier, Arthur Cezar
    Calsolari, Maria Regina
    THYROID, 2011, 21 (01) : 49 - 53